Zotiraciclib
A cyclin-dependent kinase inhibitor
| Zotiraciclib | |
|---|---|
| File:Zotiraciclib skeletal.svg | |
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | 123456-78-9 |
| PubChem | 12345678 |
| DrugBank | |
| ChemSpider | 12345678 |
| KEGG | |
Zotiraciclib is an investigational cyclin-dependent kinase (CDK) inhibitor that has been studied for its potential use in the treatment of various types of cancer. It is known by its research code TG02.
Mechanism of Action[edit]
Zotiraciclib functions by inhibiting multiple cyclin-dependent kinases, which are enzymes that play a crucial role in the regulation of the cell cycle. By inhibiting these kinases, zotiraciclib can induce cell cycle arrest and promote apoptosis in cancer cells. This mechanism is particularly effective in rapidly dividing cells, such as those found in tumors.
Clinical Development[edit]
Zotiraciclib has been evaluated in several clinical trials to assess its efficacy and safety in treating different types of cancer, including glioblastoma and other solid tumors. The drug has shown promise in preclinical studies and early-phase clinical trials, demonstrating the ability to cross the blood-brain barrier and target brain tumors effectively.
Pharmacokinetics[edit]
The pharmacokinetic profile of zotiraciclib includes its absorption, distribution, metabolism, and excretion. The drug is administered orally and has been shown to have a favorable bioavailability. It is metabolized primarily in the liver and excreted through the kidneys.
Side Effects[edit]
As with many cancer therapies, zotiraciclib can cause a range of side effects. Common adverse effects observed in clinical trials include nausea, fatigue, and hematological toxicity, such as neutropenia and thrombocytopenia.
Research and Future Directions[edit]
Ongoing research is focused on optimizing the dosing regimen of zotiraciclib and exploring its use in combination with other anticancer agents. Studies are also investigating biomarkers that may predict response to treatment, which could help tailor therapy to individual patients.
Related pages[edit]
Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa
Tired of being overweight?
Special offer:
Budget GLP-1 weight loss medications
- Semaglutide starting from $29.99/week and up with insurance for visit of $59.99 and up per week self pay.
- Tirzepatide starting from $45.00/week and up (dose dependent) or $69.99/week and up self pay
✔ Same-week appointments, evenings & weekends
Learn more:
- GLP-1 weight loss clinic NYC
- W8MD's NYC medical weight loss
- W8MD Philadelphia GLP-1 shots
- Philadelphia GLP-1 injections
- Affordable GLP-1 shots NYC
- Budget GLP-1 shots
|
WikiMD Medical Encyclopedia |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
